ARTICLE | Clinical News
Menveo regulatory update
June 20, 2011 7:00 AM UTC
FDA accepted for filing an sBLA from Novartis for Menveo to prevent invasive disease caused by Neisseria meningitides serogroups A, C, Y and W135 in infants and toddlers ages 2 months to 2 years of ag...